Related Experiment Video

Updated: Apr 4, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on

B Peter1,2, G E Winter3, K Blatt2

  • 1Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.

Leukemia
|September 10, 2015
PubMed

Insights

Midostaurin and its metabolite CGP62221 inhibit mast cell growth, while CGP52421 primarily reduces histamine release. This explains symptom improvement in systemic mastocytosis patients despite potential disease progression.

Area of Science:

  • Pharmacology
  • Oncology
  • Immunology

Background:

  • Midostaurin (PKC412) is a multikinase inhibitor for advanced systemic mastocytosis (SM).
  • Understanding midostaurin metabolites' effects is crucial for optimizing SM treatment.
  • Proteomic-based drug testing aids in evaluating kinase inhibitors.

Purpose of the Study:

  • To investigate the mast cell (MC)-targeting effects and target interaction profiles of midostaurin metabolites CGP52421 and CGP62221.
  • To compare the anti-neoplastic potential of midostaurin and its key metabolites.
  • To elucidate the mechanisms behind clinical observations in SM patients treated with midostaurin.

Main Methods:

  • Utilized proteomic profiling and drug competition assays.
  • Assessed IgE-dependent histamine secretion in basophils and MCs.
  • Evaluated cell growth inhibition and KIT dephosphorylation in HMC-1.2 cells.

Main Results:

  • Midostaurin, CGP52421, and CGP62221 suppressed histamine release (IC50 values).
  • Midostaurin and CGP62221 inhibited HMC-1.2 cell growth and KIT phosphorylation; CGP52421 showed minimal effects.
  • CGP52421 inhibited IgE-dependent histamine release but weakly inhibited MC proliferation.

Conclusions:

  • Midostaurin metabolite CGP52421 effectively reduces mediator release but has limited impact on mast cell proliferation.
  • This differential activity may explain symptom improvement in SM patients even with ongoing disease progression.
  • Proteomic analysis revealed distinct kinase target interactions for midostaurin and its metabolites.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

2.2K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.3K